Parenteral Formulation for New Class (DNA Minor Groove Binder) Anti-Infective

MGB的临床前候选药物MGB BP3是一种有效的抗感染化合物，对革兰氏阳性细菌（包括危及生命的高耐药菌株，如asMRSA）具有高效的抗感染作用。该化合物显示出不同寻常的物理化学特性，这使得溶解非常具有挑战性。因此，MGB生物制药公司被迫采用口服配方来治疗艰难梭菌感染的一小部分细菌感染。在经典仓鼠模型中，该适应症的配方最近被成功证明优于金标准药物（万古霉素）。为了能够利用这种新型药物来治疗最棘手的传染病，我们需要扩展开发中的配方，以便能够成功地生产出一种可重复且稳定的产品，能够通过静脉途径给予因耐药细菌和其他感染而有死亡风险的患者。

MGB's preclinical candidate drug MGB BP3 is a potent anti-infective compound with highpotency against Gram +ve bacteria, including life threatening highly resistant strains such asMRSA. The compound shows unusual physicochemical characteristics which makesolubilisation very challenging As a result, MGB Biopharma has been forced to adopt an oralformulation to treat just a subset of bacterial infections - that of Clostridium difficile. Theformulation for that indication was recently successfully shown to be superior to the goldstandard drug (vancomycin) in the classic Hamster model. To be able to utilise this new classof drug against the most troublesome infectious diseases we need to extend the formulationsin development to be able to successfully produce a reproducible and stable product capableof being given by the intravenous route to patients who are at risk of death due to resistantbacterial and other infections.